Sichuan Kelun-Biotech Biopharmaceutical stock

6990 · HKEX · HKD

Compare Sichuan Kelun-Biotech Biopharmaceutical
$398.40Change from previous close: −5.59%Absolute change: −$23.60

Close · November 20, 2026

Price history

−9.37% over the period

1 year: from $439.60 (November 20, 2025) to $398.40 (November 20, 2026), −9.37%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$398.40
October 30, 2026$424.80
September 30, 2026$487.00
August 31, 2026$497.20
July 31, 2026$483.80
June 30, 2026$436.20
May 29, 2026$462.00
April 30, 2026$469.40
March 31, 2026$460.00
February 27, 2026$387.40
January 30, 2026$415.40
December 31, 2025$393.40
November 28, 2025$456.40
November 20, 2025$439.60

At a glance

  • The company

    Biopharmaceutical company developing novel drugs in oncology, immunology, metabolism and other therapeutic areas

  • Latest results

    Quarter to June 30, 2026 · EPS ¥1.66

TickerLandia's take on Sichuan Kelun-Biotech Biopharmaceutical

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$339.60
52-wk high$562.50

−29.17% from the 52-week high

Analysts · 21 analysts

Average target$617.60+55.02% vs. price

Buy 20 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Sichuan Kelun-Biotech Biopharmaceutical

Compared with similar companies: very high price and very low earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Sichuan Kelun-Biotech Biopharmaceutical is pricier than similar companies

Sichuan Kelun-Biotech Biopharmaceutical's Forward P/E: 121.7, +284% against the median of a group of 11 similar companies (31.7).

Compared with 11 similar companies

Sichuan Kelun-Biotech Biopharmaceutical's metrics compared with similar companies
MetricSichuan Kelun-Biotech BiopharmaceuticalPosition in the groupBand
Forward P/E121.7High
Operating margin-0.2%Low
ROE2.9%Low
Debt/equity0.02Low
Price/book14.8High

Grey band: the middle half of the group; tick: the median; dot: Sichuan Kelun-Biotech Biopharmaceutical. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥978.34M

Latest quarter · Q2 2026

Net income

¥388.01M

Latest quarter · Q2 2026

Quarterly net margin

39.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$95.23B
P/E
553.3
EPS
$0.72
Volume
1.05M
Daily trading
€44.73M
Dividend yield
0.00%

How Sichuan Kelun-Biotech Biopharmaceutical is changing

All results
  • Revenue grew 36.8% a year on average over the last 3 years

  • Operating margin rose from −49.0% to −20.4%

  • Shares outstanding up 141.4% in 3 years

Returns

Sichuan Kelun-Biotech Biopharmaceutical returns

$1,000 invested in Sichuan Kelun-Biotech Biopharmaceutical 3 years ago, on November 20, 2023, would be worth $4,390 today: +339.01% in total, +63.72% per year. This is the price return only: dividends are excluded.

PeriodSichuan Kelun-Biotech BiopharmaceuticalHang Seng$1,000 becomes
1 month−14.87%−6.10%$851
6 months−8.83%−12.63%$912
Year to date+1.27%−12.56%$1,013
1 year−9.37%−13.26%$906
3 years+339.01%+26.06%$4,390

Over the last 6 months it has done better than 28% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Sichuan Kelun-Biotech Biopharmaceutical: technical analysis

Sichuan Kelun-Biotech Biopharmaceutical is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 31.0% below its all-time closing high ($577.50, October 8, 2025).

Trend
Downward
RSI (14 sessions)
34
Between 30 and 70
vs 200-session average
−12.88%

Active signals

  • Death cross: the 50-session average has crossed below the 200-session average.

    since November 19, 2026

Support and resistance

Price areas where Sichuan Kelun-Biotech Biopharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$453.95+13.94%4 touches, last on September 28, 2026
  2. Resistance$436.27+9.50%3 touches, last on October 9, 2026
  3. Resistance$416.30+4.49%2 touches, last on May 18, 2026
  4. Last price$398.40
  5. Support$392.37−1.51%6 touches, last on November 3, 2026

Volatility and risk

Over the last year it has moved roughly in line with the Hang Seng.

Beta (1 year) vs Hang Seng
0.96
Volatility (60 sessions, annualised)
47.9%
Largest fall in the last year
−28.83%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Sichuan Kelun-Biotech Biopharmaceutical and its competitors

With 2,300 employees, Sichuan Kelun-Biotech develops, manufactures and sells novel medicines for oncology, immunology and metabolic conditions, serving patients in China and in overseas markets. Its pipeline rests largely on antibody-drug conjugates, among them Sac-TMT, a TROP2-directed candidate that can be used alone or alongside other treatments for advanced solid tumors, and trastuzumab botidotin for HER2-positive tumors. Further candidates include a CLDN18.2 conjugate, a Nectin-4 conjugate, the PD-L1 antibody tagitanlimab and the RET inhibitor A400.

Headquarters
Chengdu, China
Employees
2,300
Founded
2016
Chief executive
Junyou Ge
Sichuan Kelun-Biotech Biopharmaceutical and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Sichuan Kelun-Biotech Biopharmaceutical6990$12.15B-0.2%—−8.83%
Sino Biopharmaceutical1177$11.65B28.2%34.2−1.26%
Pharmaron Beijing300759$10.59B14.0%39.3+44.36%
Innovent Biologics1801$17.82B7.4%105.4+0.88%
ALTEOGEN196170$9.05B47.2%97.1−36.93%
Haisco Pharmaceutical Group002653$8.97B21.1%44.1+0.54%

Same industry or related industries, similar size. Compare Sichuan Kelun-Biotech Biopharmaceutical with its competitors · Full profile